Novobind Livestock Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Novobind Livestock Therapeutics Inc. - overview
Established
2012
Location
Vancouver, BC, Canada
Primary Industry
Biotechnology
About
Based in Vancouver, Canada, and founded in 2012 by Filip Van Petegem, Hamlet Hovanessian Abnousi, Robert Fraser, Slade Loutet, and Sylvia Cheung, Novobind Livestock Therapeutics Inc. , a. k. a.
NovoBind operates as a biotechnology company that focuses on developing novel biotherapeutic solutions (NBXs) based on single-domain antibodies and complementary to conventional treatments. In April 2023, NovoBind received USD 0. 030 million in grant funding from Invest Nova Scotia. The company provides single domain antibodies (NBXs) that target pathogens that affect food production and food safety losses and have been materially affected by antibacterial resistance, regulatory ban, and changing human sentiments.
These NBXs can be incorporated into feed, feed additives, water, or egg-based applications.
Current Investors
Seventure Partners, Lallemand Inc., Natural Products Canada
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Biopharmaceuticals
Website
www.novobind.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.